Essa Al Mansor

Dr. Essa Al Mansor


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ZIZafar Iqbal
Zafar Iqbal
AAAbdulkareem Abdulghani Algarni
Abdulkareem Abdulghani Algarni
YTYaqob Taleb
Yaqob Taleb
SASultan Alqahtani
Sultan Alqahtani
MSMuhammad Farooq Sabar
Muhammad Farooq Sabar
SRSohail Rao
Sohail Rao
Background/Objectives: Blast-crisis chronic myeloid leukemia (BC-CML) represents a genomically unstable, therapeutically refractory phase driven by clonal evolution beyond BCR::ABL1 dependence. Clinical outcomes remain poor, with median survival under one year. Mutation-level analyses inadequately resolve biological heterogeneity or inform rational patient-specific therapy. We therefore implemented a mutational process–anchored framework integrating genomics, machine learning (ML), and artificial intelligence (AI)–guided drug prioritization at single-patient resolution. Methods: Whole-exome sequencing, COSMIC mutational signature deconvolution, unsupervised ML clustering, and AI-guided pharmacogenomic prioritization were applied to 224 patients with CML (190 chronic phase, 15 accelerated phase, 19 blast crisis) and 19 healthy controls. Results: Mutation burden increased significantly with disease progression, and blast crisis exhibited complex co-mutation architectures involving TP53, BRCA2, IDH1/2, DNMT3A, JAK2, and CSF3R. While gene-level patterns were heterogeneous, dominant mutational processes converged across cases. COSMIC signature extraction stratified BC-CML into three biologically coherent clusters: homologous recombination deficiency/genomic instability (Signatures 3/5), epigenetic–metabolic dysregulation (Signatures 1/2), and oxidative stress–associated cytokine signaling mutagenesis (Signatures 13/18). These process-defined states mechanistically link DNA repair failure, chromatin remodeling, and inflammatory signaling to blast transformation. Integration with an AI-guided pharmacogenomic framework translated signature biology into rational, cluster-specific therapeutic prioritization, including PARP inhibition, IDH targeting, CDK4/6 blockade, JAK pathway inhibition, and redox-modulating strategies. Dominant signature resolution reduced multidrug ambiguity and supported single-patient therapeutic parsimony. External concordance assessment across independent pharmacogenomic datasets supported predicted vulnerabilities. Conclusions: This study establishes a mechanistically interpretable, process-anchored precision oncology framework for BC-CML linking genomic architecture to actionable therapeutic decision-making warranting clinical validation. The approach can further be implemented for AL-AI-prioritized precision treatment of other relapsed, refractory and metastatic cancers.

26 June 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Kaveh FarrokhiKaveh Farrokhi
Kaveh Farrokhi
HMHoria Marginean
Horia Marginean
AAAnas A. Alghamdi
Anas A. Alghamdi
EMEssa Al Mansor
Essa Al Mansor
SDShaan Dudani
Shaan Dudani
Michael VickersMichael Vickers
Michael Vickers
Background: The impact of adjuvant chemotherapy (AC) on outcomes in real-world patients with locally advanced rectal cancer (LARC) remains uncertain. Methods: Consecutive patients with LARC (stage II/III) undergoing neoadjuvant chemoradiation before curative-intent surgery from 2005 to 2013 were identified in the Canadian Health Outcomes Research Database. The impact of AC on clinical outcomes, including disease-free survival (DFS) and overall survival (OS), was evaluated using the Kaplan–Meier method and Cox proportional hazards modeling. Results: A total of 1448 patients had sufficient data available to be included for analysis with 1085 (74.9%) receiving AC. Of AC patients, 40.5% received oxaliplatin-based treatments. With a median follow-up of 66.43 months, the 5-year DFS rate was 67.7% (95% CI: 64.5–70.1%) vs. 58.7% (95% CI: 52.8–64.2%) in the AC group and non-AC group, respectively (p < 0.001). The 5-year OS rate of the whole cohort was 74.3% (95% CI: 71.5–76.85%) while the 5-year OS rate of the AC group was 77.8% (95% CI: 74.7–80.6%) compared with 63.8% (95% CI: 57.9–69.2%) for the non-AC group (p < 0.001). On multivariate analysis, patients who received AC had improved DFS (HR 0.6, 95% CI: 0.49–0.73, p < 0.001) and OS (HR 0.46, 95% CI: 0.36–0.58, p < 0.001). Conclusions: This large multi-institutional database analysis supports the use of AC in real-world LARC patients treated with nCRT followed by surgical resection.

29 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LALubna Alnaim
Lubna Alnaim
AAAbdulkareem AlGarni
Abdulkareem AlGarni
Azfar IshaquiAzfar Ishaqui
Azfar Ishaqui
SASultan Alqahtani
Sultan Alqahtani
MAMuhammad Alshuaibi
Muhammad Alshuaibi
ZIZafar Iqbal
Zafar Iqbal
Cancer is increasingly recognized as a metabolic disease influenced by nutritional factors, with multi-omics technologies and artificial intelligence (AI), particularly machine learning (ML), enabling integrative analyses of diet, metabolism, and tumor biology interactions. This study aimed to synthesize evidence on these approaches for understanding the nutrition–metabolism–cancer axis and assess their translational potential in oncology, especially in low-resource settings. A PRISMA-compliant systematic review and meta-analysis searched PubMed, EMBASE, and Cochrane databases from 2018 to 2025, including studies on human cancers using ≥2 omics layers integrated via AI/ML and addressing nutritional/metabolic exposures. Random-effects pooling evaluated area under the curve (AUC), odds ratios (OR), and clinical endpoints, with subgroup analyses and quality assessments via QUADAS-2, ROBINS-I, TRIPOD, and PRISMA-AI. From 4812 records, 42 studies were included, yielding a pooled AUC of 0.88 (95% CI: 0.86–0.91) and OR of 2.4 (95% CI: 1.2–3.5), demonstrating encouraging but early-stage exploratory evidence of predictive performance. Cancer-specific signatures emerged in colorectal, breast, pancreatic, liver, and hematologic malignancies. A conceptual translational framework was proposed, integrating nutrition, omics, AI/ML, and oncology to illustrate a potential implementation pathway for developing countries like Saudi Arabia. These findings represent preliminary, hypothesis-generating evidence; the proposed framework requires prospective validation before clinical deployment, particularly in resource-limited settings.